A key Australian health committee has recommended Wegovy for subsidized access. This drug targets adults with existing heart conditions and obesity. The decision aims to help vulnerable individuals manage high treatment costs. Strict eligibility criteria will apply, focusing on those with significant cardiovascular risk. This move could pave the way for wider access to weight management medications.